Byondis B.V.: Byondis and medac Enter Into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine (SYD985)

SYD985 Marketing Authorization Application Soon to Be Submitted to the EMA NIJMEGEN, Netherlands and WEDEL, Germany, May 3, 2022 /PRNewswire/ -- Byondis B.V., an independent, Dutch clinical

Related Keywords

Germany ,Netherlands ,United Kingdom ,Nijmegen ,Gelderland ,Dutch ,Prnewswire Byondis ,Marco Timmers ,Kostenloser Wertpapierhandel ,Jacques Lemmens ,European Medicines Agency ,Regulatory Agency ,Authorization Application Soon ,Collaboration Agreement ,Supply Agreement ,United Kingdom Medicines ,Byondis Founder ,Chairman Jacques Lemmens ,Managing Director ,Marketing Authorization Application ,Next Generation Antibody Drug ,Good Manufacturing Practice ,Byondis ,Medac ,Winter ,Into ,License ,Collaboration ,Supply ,Agreements ,Anti ,Ther2 ,Rastuzumab ,Uocarmazine ,Yd985 ,